{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:19:04Z","timestamp":1792624744432,"version":"4.5.0"},"reference-count":135,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.eclinm.2019.12.007","type":"journal-article","created":{"date-parts":[[2020,1,5]],"date-time":"2020-01-05T22:30:31Z","timestamp":1578263431000},"page":"100237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"special_numbering":"C","title":["Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis"],"prefix":"10.1016","volume":"18","author":[{"given":"Michael J.","family":"Zoratti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Siddiqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5617-4366","authenticated-orcid":false,"given":"Rita E.","family":"Morassut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena","family":"Zeraatkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"van Holten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Druyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2019.12.007_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(18)32277-3","article-title":"Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model","author":"Heffernan","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(18)32750-8","article-title":"How feasible is the global elimination of HCV infection?","author":"Wiktor","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.eclinm.2019.12.007_bib0003","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJMp1812959","article-title":"Brazil's fight against hepatitis C \u2013 universalism, local production, and patents","volume":"380","author":"da Fonseca","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.eclinm.2019.12.007_bib0004","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1056\/NEJMp1813728","article-title":"Universal medicine access through lump-sum remuneration \u2013 Australia's approach to hepatitis C","volume":"380","author":"Moon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0005","series-title":"Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection","year":"2018"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0006","series-title":"Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection: web annex 3.1: adult hepatitis C virus treatment systematic review","author":"Zoratti","year":"2018"},{"issue":"7","key":"10.1016\/j.eclinm.2019.12.007_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the prisma statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0008","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ (Clin Res Ed)"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0009","series-title":"Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Updated version","year":"2016"},{"issue":"9","key":"10.1016\/j.eclinm.2019.12.007_bib0010","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Stat Med"},{"issue":"3","key":"10.1016\/j.eclinm.2019.12.007_bib0011","doi-asserted-by":"crossref","first-page":"48","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in r with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"issue":"5","key":"10.1016\/j.eclinm.2019.12.007_bib0012","doi-asserted-by":"crossref","first-page":"15","DOI":"10.18637\/jss.v049.i05","article-title":"Closing the gap between methodologists and end-users: r as a computational back-end","volume":"49","author":"Wallace","year":"2012","journal-title":"J Stat Softw"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0013","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ (Clin Res Ed)"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0014","unstructured":"CLARITY Group at McMaster University. Tools to assess risk of bias in cohort studies, case control studies, randomized controlled trials, and longitudinal symptom research studies aimed at the general population 2013. Available from: https:\/\/www.evidencepartners.com\/resources\/methodological-resources\/."},{"issue":"12","key":"10.1016\/j.eclinm.2019.12.007_bib0015","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jclinepi.2011.04.014","article-title":"GRADE guidelines: 8. Rating the quality of evidence\u2013indirectness","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"10.1016\/j.eclinm.2019.12.007_bib0016","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","article-title":"GRADE guidelines: 7. Rating the quality of evidence\u2013inconsistency","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"10.1016\/j.eclinm.2019.12.007_bib0017","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","article-title":"GRADE guidelines: 5. Rating the quality of evidence\u2013publication bias","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"10.1016\/j.eclinm.2019.12.007_bib0018","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jclinepi.2011.06.004","article-title":"GRADE guidelines: 9. Rating up the quality of evidence","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.eclinm.2019.12.007_bib0019","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines: 4. Rating the quality of evidence\u2013study limitations (risk of bias)","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"7650","key":"10.1016\/j.eclinm.2019.12.007_bib0020","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ (Clin Res Ed)"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0021","article-title":"Effect of sofosbuvir plus daclatasvir in hepatitis c virus genotype-4 patients: promising effect on liver fibrosis","author":"Abdel-Aziz","year":"2017","journal-title":"J Clin Exp Hepatol"},{"issue":"4","key":"10.1016\/j.eclinm.2019.12.007_bib0022","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/hep.28706","article-title":"Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection","volume":"64","author":"Abergel","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0023","unstructured":"Alqahtani S, Afdahl NH, Zeuzem S, Gordon SC, Mangia A, Kwo PY, et al. Safety ofledipasvir sofosbuvir with and without ribavirin for the treatment of patientswith chronic HCV genotype 1 infection an analysis of the phase 3 ion trials.Hepatol Int 9(1 Suppl. 1):S59\u201360."},{"issue":"1","key":"10.1016\/j.eclinm.2019.12.007_bib0024","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/hep.27890","article-title":"Safety and tolerability of ledipasvir\/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ion trials","volume":"62","author":"Alqahtani","year":"2015","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.eclinm.2019.12.007_bib0025","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/apt.13696","article-title":"Comparative effectiveness of ledipasvir\/sofosbuvir +\/- ribavirin vs. ombitasvir\/paritaprevir\/ritonavir\u00a0+\u00a0dasabuvir +\/- ribavirin in 6961 genotype 1 patients treated in routine medical practice","volume":"44","author":"Backus","year":"2016","journal-title":"Alimen Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.eclinm.2019.12.007_bib0026","doi-asserted-by":"crossref","first-page":"S1091","DOI":"10.1016\/S0016-5085(17)33678-8","article-title":"Treatment of patients with chronic hepatitis genotype 3 infection with\/without cirrhosis with sofosbuvir and daclatasvir therapy","volume":"152","author":"Bansal","year":"2017","journal-title":"Gastroenterology"},{"issue":"22","key":"10.1016\/j.eclinm.2019.12.007_bib0027","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourliere","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eclinm.2019.12.007_bib0028","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1473-3099(15)70050-2","article-title":"Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)","volume":"15","author":"Bourliere","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0029","first-page":"1","article-title":"Health-Related quality of life in chronic HCV-Infected patients switching to pegylated-interferon-free regimens (ANRS CO20 cupic cohort study and sirius trial)","author":"Carrieri","year":"2017","journal-title":"Patient"},{"issue":"5 Supplement 1","key":"10.1016\/j.eclinm.2019.12.007_bib0030","first-page":"S102","article-title":"Sofosbuvir\/Velpatasvir for the treatment of HCV in patients with decompensated liver disease: the ASTRAL-4 study","volume":"100","author":"Charlton","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0031","doi-asserted-by":"crossref","first-page":"S527","DOI":"10.1016\/S0168-8278(17)31456-3","article-title":"CERTAIN-1: efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis","volume":"66","author":"Chayama","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.eclinm.2019.12.007_bib0032","doi-asserted-by":"crossref","first-page":"S528","DOI":"10.1016\/S0168-8278(17)31457-5","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection with and without cirrhosis","volume":"66","author":"Chayama","year":"2017","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.eclinm.2019.12.007_bib0033","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/jgh.13305","article-title":"Ledipasvir\/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus","volume":"31","author":"Chuang","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.eclinm.2019.12.007_bib0034","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/apt.13925","article-title":"Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection","volume":"45","author":"Cornberg","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"5 Supplement 1","key":"10.1016\/j.eclinm.2019.12.007_bib0035","first-page":"S136","article-title":"Clinical benefits of successful treatment in HCV infected patients with decompensated cirrhosis treated with sofosbuvir\/velpatasvir","volume":"100","author":"Curry","year":"2016","journal-title":"Transplantation"},{"issue":"27","key":"10.1016\/j.eclinm.2019.12.007_bib0036","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2019.12.007_bib0037","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","article-title":"Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C","volume":"65","author":"Desnoyer","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.eclinm.2019.12.007_bib0038","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1473-3099(16)30408-X","article-title":"Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet acute HCV IV): an open-label, single-arm, phase 2 study","volume":"17","author":"Deterding","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"1 Supplement 1","key":"10.1016\/j.eclinm.2019.12.007_bib0039","first-page":"416A","article-title":"Six weeks of sofosbuvir\/ledipasvir treatment of acute hepatitis C virus genotype 1 monoinfection: final results of the the German hepnet acute HCV IV study","volume":"63","author":"Deterding","year":"2016","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.eclinm.2019.12.007_bib0040","doi-asserted-by":"crossref","first-page":"818","DOI":"10.7326\/M15-1000","article-title":"Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis c virus infection","volume":"163","author":"Everson","year":"2015","journal-title":"Ann Intern Med"},{"issue":"27","key":"10.1016\/j.eclinm.2019.12.007_bib0041","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.eclinm.2019.12.007_bib0042","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/cid\/ciw387","article-title":"Effectiveness and safety of sofosbuvir-based regimens for chronic HCV genotype 3 infection: results of the HCV-target study","volume":"63","author":"Feld","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0043","doi-asserted-by":"crossref","first-page":"S300","DOI":"10.1016\/S0168-8278(17)30917-0","article-title":"Treatment of \u201cacute\u201d hepatitis C virus in human immunodeficiency virus-infected men with short-course sofosbuvir\/ledipasvir","volume":"66","author":"Fierer","year":"2017","journal-title":"J Hepatol"},{"issue":"1 Supplement 1","key":"10.1016\/j.eclinm.2019.12.007_bib0044","first-page":"453A","article-title":"Safety and efficacy of the combination ombitasvir\/ paritaprevir\/ritonavir +\/- dasabuvir in HCV genotype 1-or 4-mono-infected patients from the French ANRS Co22 hepather cohort","volume":"63","author":"Fontaine","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0045","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0168-8278(17)30269-6","article-title":"EXPEDITION-I: efficacy and safety of glecaprevir\/pibrentasvir in adults with chronic hepatitis C virus genotype 1, 2, 4, 5 or 6 infection and compensated cirrhosis","volume":"66","author":"Forns","year":"2017","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.eclinm.2019.12.007_bib0046","doi-asserted-by":"crossref","first-page":"S1061","DOI":"10.1016\/S0016-5085(17)33583-7","article-title":"EXPEDITION-I: efficacy and safety of glecaprevir\/pibrentasvir in adults with chronic hepatitis C virus genotype 1, 2, 4, 5 or 6 infection and compensated cirrhosis","volume":"152","author":"Forns","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial","author":"Forns","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"27","key":"10.1016\/j.eclinm.2019.12.007_bib0048","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0049","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0168-8278(17)30326-4","article-title":"ENDURANCE-3: safety and efficacy of glecaprevir\/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-na\u00efve HCV genotype 3-infected patients without cirrhosis","volume":"66","author":"Foster","year":"2017","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.eclinm.2019.12.007_bib0050","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.eclinm.2019.12.007_bib0051","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1053\/j.gastro.2016.07.020","article-title":"High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis","volume":"151","author":"Gane","year":"2016","journal-title":"Gastroenterology"},{"issue":"16","key":"10.1016\/j.eclinm.2019.12.007_bib0052","article-title":"Ledipasvir\/sofosbuvir with or without ribavirin for the treatment of patients with genotype 2-6 chronic HCV infection: summary results from four phase ii studies","volume":"110","author":"Gane","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.eclinm.2019.12.007_bib0053","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1053\/j.gastro.2015.07.063","article-title":"Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection","volume":"149","author":"Gane","year":"2015","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.eclinm.2019.12.007_bib0054","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1053\/j.gastro.2017.01.017","article-title":"Efficacy of ledipasvir plus sofosbuvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2 infection","volume":"152","author":"Gane","year":"2017","journal-title":"Gastroenterology"},{"issue":"1 Supplement 1","key":"10.1016\/j.eclinm.2019.12.007_bib0055","first-page":"S102","article-title":"Sofosbuvir\/velpatasvir for 12 weeks results in high SVR12 rates in patients with indeterminate genotypes: an integrated analysis of efficacy from the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies","volume":"11","author":"Gee Lim","year":"2017","journal-title":"Hepatol Int"},{"issue":"11","key":"10.1016\/j.eclinm.2019.12.007_bib0056","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/cid\/ciw579","article-title":"Efficacy and safety of sofosbuvir\/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 astral trials","volume":"63","author":"Grebely","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.eclinm.2019.12.007_bib0057","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/cid\/ciw580","article-title":"Efficacy and safety of ledipasvir\/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: analysis of phase 3 ion trials","volume":"63","author":"Grebely","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.eclinm.2019.12.007_bib0058","doi-asserted-by":"crossref","first-page":"S1099","DOI":"10.1016\/S0016-5085(17)33702-2","article-title":"Efficacy and safety of sofosbuvir and daclatasvir for 8 weeks in treatment-naive non-cirrhotic patients with chronic HCV genotype 3 infection","volume":"152","author":"Hezode","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0059","doi-asserted-by":"crossref","first-page":"S299","DOI":"10.1016\/S0168-8278(17)30916-9","article-title":"Efficacy and safety of sofosbuvir and daclatasvir for 8 weeks in treatment-na\u00efve non-cirrhotic patients with chronic hepatitis C virus genotype 3 infection","volume":"66","author":"Hezode","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0060","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.12721","article-title":"Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis c virus genotypes 1-4 and 6 in Myanmar: real-world experience","author":"Hlaing","year":"2017","journal-title":"J Viral Hepatol"},{"issue":"1 Supplement 1","key":"10.1016\/j.eclinm.2019.12.007_bib0061","first-page":"459A","article-title":"Efficacy and safety of DAAs therapy in hepatitis C: a multicenter real-world cohort of chronic hepatitis C patients","volume":"63","author":"Ide","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0062","doi-asserted-by":"crossref","DOI":"10.1111\/hepr.12898","article-title":"Clinical evaluation of sofosbuvir\/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir\/asunaprevir therapy","author":"Iio","year":"2017","journal-title":"Hepatology Res"},{"issue":"10","key":"10.1016\/j.eclinm.2019.12.007_bib0063","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/cid\/ciw567","article-title":"Sofosbuvir and ledipasvir for 8 weeks for the treatment of chronic hepatitis c virus (HCV) infection in HCV-Monoinfected and HIV-HCV-Coinfected individuals: results from the German hepatitis c cohort (GECCO-01)","volume":"63","author":"Ingiliz","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"1 Supplement 1","key":"10.1016\/j.eclinm.2019.12.007_bib0064","first-page":"1010A","article-title":"Ledipasvir\/Sofosbuvir for 8 weeks results in high SVR rates in treatment-naive patients with chronic HCV infection and HIV\/HCV co-infection","volume":"63","author":"Isakov","year":"2016","journal-title":"Hepatology"},{"issue":"2 SUPPL. 1","key":"10.1016\/j.eclinm.2019.12.007_bib0065","doi-asserted-by":"crossref","first-page":"S773","DOI":"10.1016\/S0168-8278(16)01508-7","article-title":"The tolerability of SOF\/VEL for 12 weeks in >1000 patients treated in the astral-1, astral-2, and astral-3 studies: an integrated safety analysis","volume":"64","author":"Jacobson","year":"2016","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.eclinm.2019.12.007_bib0066","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.eclinm.2019.12.007_bib0067","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s12072-016-9755-0","article-title":"Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients","volume":"10","author":"Ji","year":"2016","journal-title":"Hepatol Int"},{"issue":"9","key":"10.1016\/j.eclinm.2019.12.007_bib0068","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1473-3099(15)00157-7","article-title":"Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study","volume":"15","author":"Kohli","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"9973","key":"10.1016\/j.eclinm.2019.12.007_bib0069","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(14)61228-9","article-title":"Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study","volume":"385","author":"Kohli","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0070","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S0168-8278(17)30307-0","article-title":"Sustained virologic response by ledipasvir\/sofosbuvir reduces the incidence of hepatocellular carcinoma in Japanese patients with HCV genotype 1 infection. Comparison with simeprevir with peginterferon plus ribavirin","volume":"66","author":"Korenaga","year":"2017","journal-title":"J Hepatol"},{"issue":"1 Supplement 1","key":"10.1016\/j.eclinm.2019.12.007_bib0071","first-page":"S111","article-title":"Sofosbuvir\/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1: the phase 3 ASTRAL-5 study","volume":"11","author":"Kottilil","year":"2017","journal-title":"Hepatol Int"},{"issue":"11","key":"10.1016\/j.eclinm.2019.12.007_bib0072","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/liv.13165","article-title":"On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir","volume":"36","author":"Kowdley","year":"2016","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.eclinm.2019.12.007_bib0073","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1\u20136 without cirrhosis","volume":"67","author":"Kwo","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0074","doi-asserted-by":"crossref","unstructured":"Lawitz EZS, Stedman CA, Poordad F, Mir HM, Seyedkazemi S, Hyland RH, et al.Sofosbuvir-based regimens for patients with hepatitis C virus genotype 3 infection: summary results from the valence, lonestar-2, and electron-2 studies. Gastroenterology. 148(4 Suppl. 1):S1085\u2013S6.","DOI":"10.1016\/S0016-5085(15)33707-0"},{"issue":"6","key":"10.1016\/j.eclinm.2019.12.007_bib0075","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s12072-016-9726-5","article-title":"A phase IIIb study of ledipasvir\/sofosbuvir fixed-dose combination tablet in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus","volume":"10","author":"Lim","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0076","doi-asserted-by":"crossref","first-page":"S731","DOI":"10.1016\/S0168-8278(17)31951-7","article-title":"Improved virological outcomes and excellent safety profile in genotype 3 HCV-infected cirrhotic patients after an extended 24- weeks course of daclatasvir, sofosbuvir\u00a0+\u00a0ribavirin: insights froma real-life multicenter study","volume":"66","author":"Lionetti","year":"2017","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.eclinm.2019.12.007_bib0077","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/liv.13069","article-title":"The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin","volume":"36","author":"Mangia","year":"2016","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.eclinm.2019.12.007_bib0078","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3851\/IMP3120","article-title":"Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin","volume":"22","author":"McPhee","year":"2017","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0079","article-title":"Impact of direct acting antiviral therapy for treatment of hepatitis c genotypes 1, 3 and 4: a real life experience from India","author":"Mehta","year":"2017","journal-title":"J Clin Exp Hepatol"},{"issue":"6","key":"10.1016\/j.eclinm.2019.12.007_bib0080","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","article-title":"Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial","volume":"15","author":"Mizokami","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.eclinm.2019.12.007_bib0081","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1358\/dot.2016.52.2.2449840","article-title":"Ledipasvir\/sofosbuvir fixed-dose combination for treatment of hepatitis C virus genotype 4 infection","volume":"52","author":"Nehra","year":"2016","journal-title":"Drugs Today"},{"issue":"4","key":"10.1016\/j.eclinm.2019.12.007_bib0082","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.eclinm.2019.12.007_bib0083","first-page":"e32","article-title":"All-Oral 12-wek combination treatment with daclatasvir (DCV) and sofosbuvir (SOF) in patients infected with HCV genotype (GT) 3: aLLY-3 phase 3 study","volume":"26","author":"Nelson","year":"2015","journal-title":"Canad J Infect Dis Med Microbiol"},{"issue":"7","key":"10.1016\/j.eclinm.2019.12.007_bib0084","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00535-016-1290-1","article-title":"NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b","volume":"52","author":"Ogawa","year":"2017","journal-title":"J Gastroenterol"},{"issue":"1 Supplement 1","key":"10.1016\/j.eclinm.2019.12.007_bib0085","first-page":"S1012","article-title":"Effectiveness and safety of sofosbuvir plus ledipasvir for HCV genotype 1b patients with compensated cirrhosis","volume":"11","author":"Ogawa","year":"2017","journal-title":"Hepatol Int"},{"issue":"2 SUPPL. 1","key":"10.1016\/j.eclinm.2019.12.007_bib0086","doi-asserted-by":"crossref","first-page":"S774","DOI":"10.1016\/S0168-8278(16)01509-9","article-title":"Baseline clinical and laboratory parameters associated with clinical benefits of successful hcvtreatment with sofosbuvir\/velpatasvir in decompensated cirrhotic patients","volume":"64","author":"O'Leary","year":"2016","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.eclinm.2019.12.007_bib0087","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jama.2015.1373","article-title":"Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection","volume":"313","author":"Osinusi","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0088","doi-asserted-by":"crossref","first-page":"S294","DOI":"10.1016\/S0168-8278(17)30904-2","article-title":"Safety and efficacy of elbasvir and grazoprevir with or without ribavirin for the treatment of hepatitis C virus genotype 1: results of the hepatitis C virus-TARGET study","volume":"66","author":"Pearlman","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0089","first-page":"17","article-title":"Efficacy and safety of new direct antiviral agents in HCV infected patients with diffuse large b cell non-hodgkin lymphoma","volume":"17","author":"Persico","year":"2017","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.eclinm.2019.12.007_bib0090","doi-asserted-by":"crossref","first-page":"809","DOI":"10.7326\/M15-1014","article-title":"Sofosbuvir plus velpatasvir combination therapy for treatment- Experienced patients with genotype 1 or 3 hepatitis C virus infection","volume":"163","author":"Pianko","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0091","article-title":"Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients","volume":"10","author":"Pol","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0092","doi-asserted-by":"crossref","DOI":"10.1002\/hep.29081","article-title":"Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment","author":"Poordad","year":"2017","journal-title":"Hepatology"},{"issue":"2 SUPPL. 1","key":"10.1016\/j.eclinm.2019.12.007_bib0093","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1016\/S0168-8278(16)01668-8","article-title":"High efficacy of ABT-493 and ABT-530 in HCV genotype 1 infected patients who have failed direct-acting antiviral-containing regimens: the Magellan-I study","volume":"64","author":"Poordad","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0094","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/S0168-8278(17)30432-4","article-title":"MAGELLAN-1, part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure","volume":"66","author":"Poordad","year":"2017","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.eclinm.2019.12.007_bib0095","doi-asserted-by":"crossref","first-page":"S1057","DOI":"10.1016\/S0016-5085(17)33570-9","article-title":"MAGELLAN-1, part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure","volume":"152","author":"Poordad","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.eclinm.2019.12.007_bib0096","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/apt.13823","article-title":"All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-target database","volume":"45","author":"Reddy","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0097","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/S0168-8278(17)30375-6","article-title":"Sofosbuvir plus daclatasvir for hepatitis C virus-cryoglobulinemia vasculitis (HCV-CryoVas): vascuvaldic 2 study","volume":"66","author":"Saadoun","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.eclinm.2019.12.007_bib0098","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/j.gastro.2017.03.006","article-title":"Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-Associated cryoglobulinemia vasculitis","volume":"153","author":"Saadoun","year":"2017","journal-title":"Gastroenterology"},{"issue":"1 Supplement 1","key":"10.1016\/j.eclinm.2019.12.007_bib0099","first-page":"S109","article-title":"Ledipasvir\/sofosbuvir for 8 or 12 weeks with or without ribavirin in HCV genotype 4 patients in Egypt","volume":"11","author":"Shiha","year":"2017","journal-title":"Hepatol Int"},{"issue":"12","key":"10.1016\/j.eclinm.2019.12.007_bib0100","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1093\/cid\/civ170","article-title":"Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy","volume":"60","author":"Sidharthan","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"13","key":"10.1016\/j.eclinm.2019.12.007_bib0101","article-title":"A randomized controlled trial of sofosbuvir\/GS-5816 fixed dose combination for 12 weeks compared to sofosbuvir with ribavirin for 12 weeks in genotype 2 HCV infected patients: the phase 3 ASTRAL-2 study","volume":"62","author":"Sulkowski","year":"2015","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.eclinm.2019.12.007_bib0102","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/cid\/ciw507","article-title":"No evidence of reactivation of hepatitis b virus among patients treated with ledipasvir-sofosbuvir for hepatitis C virus infection","volume":"63","author":"Sulkowski","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.eclinm.2019.12.007_bib0103","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2016.08.004","article-title":"Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis c virus infection and factors associated with sustained virologic response","volume":"151","author":"Terrault","year":"2016","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.eclinm.2019.12.007_bib0104","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1089\/aid.2015.0170","article-title":"Interferon-Free treatment of hepatitis c virus in HIV\/hepatitis C virus-coinfected subjects results in increased serum low-density lipoprotein concentration","volume":"32","author":"Townsend","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"10.1016\/j.eclinm.2019.12.007_bib0105","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/QAD.0000000000000903","article-title":"Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir","volume":"30","author":"Townsend","year":"2016","journal-title":"Aids"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0106","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection","author":"Toyoda","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0107","doi-asserted-by":"crossref","first-page":"S519","DOI":"10.1016\/S0168-8278(17)31441-1","article-title":"Use of the 6 million viral load cut-off to guide treatment duration with ledipasvir\/sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection: results from the German hepatitis C-Registry (DHC-R)","volume":"66","author":"Vermehren","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0108","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jcv.2017.02.008","article-title":"Comparison of on-treatment HCV RNA during direct antiviral therapy using two different COBAS TaqMan HCV assays","volume":"89","author":"Vermehren","year":"2017","journal-title":"J Clin Virol"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0109","article-title":"Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of hcv genotype 2 infection: results of the real-world, clinical practice HCV-target study","volume":"13","author":"Welzel","year":"2016","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.eclinm.2019.12.007_bib0110","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/hep.28334","article-title":"Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: a retrospective analysis of phase 3 data","volume":"63","author":"Wilder","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.eclinm.2019.12.007_bib0111","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/cid\/civ874","article-title":"Successful retreatment of chronic HCV genotype-1 infection with ledipasvir and sofosbuvir after initial short course therapy with direct-acting antiviral regimens","volume":"62","author":"Wilson","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2019.12.007_bib0112","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/cid\/cix260","article-title":"Sofosbuvir and velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type 1: an open-label, phase 3 study","volume":"65","author":"Wyles","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0113","first-page":"187","article-title":"SOF\/VEL single-tablet regimen in HCV mono-infected and HIV\/HCV co-infected patients: comparison of efficacy and safety data from phase 3 clinical trials","volume":"19","author":"Wyles","year":"2016","journal-title":"J Int AIDS Soc. Conf.: Int Congr Drug Therapy HIV Infect"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0114","first-page":"17","article-title":"Response tailored protocol versus the fixed 12Weeks course of dual sofosbuvir\/daclatasvir treatment in Egyptian patients with chronic hepatitis c genotype-4 infection: a randomized, open-label, non-inferiority trial","volume":"17","author":"Yakoot","year":"2017","journal-title":"EBioMedicine"},{"issue":"376","key":"10.1016\/j.eclinm.2019.12.007_bib0115","article-title":"Asian patients with hepatitis C (HCV) genotype 1 treated with ledipasvir and sofosbuvir (LDV\/SOF) experience very high efficacy and improvement of health-related quality of life (HRQL)","volume":"31","author":"Younossi","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"issue":"6 Spec No.","key":"10.1016\/j.eclinm.2019.12.007_bib0116","first-page":"SP205","article-title":"Real-world outcomes of ledipasvir\/sofosbuvir in treatment-naive patients with hepatitis C","volume":"22","author":"Younossi","year":"2016","journal-title":"Am J Manag Care"},{"issue":"2","key":"10.1016\/j.eclinm.2019.12.007_bib0117","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S2468-1253(16)30009-7","article-title":"Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial","volume":"1","author":"Younossi","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.eclinm.2019.12.007_bib0118","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jhep.2016.02.042","article-title":"Sofosbuvir\/velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 placebo-controlled trial","volume":"65","author":"Younossi","year":"2016","journal-title":"J Hepatol"},{"issue":"33","key":"10.1016\/j.eclinm.2019.12.007_bib0119","doi-asserted-by":"crossref","first-page":"e4243","DOI":"10.1097\/MD.0000000000004243","article-title":"Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir","volume":"95","author":"Younossi","year":"2016","journal-title":"Medicine"},{"issue":"8","key":"10.1016\/j.eclinm.2019.12.007_bib0120","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/cid\/ciw496","article-title":"Ribavirin-free regimen with sofosbuvir and velpatasvir is associated with high efficacy and improvement of patient-reported outcomes in patients with genotypes 2 and 3 chronic hepatitis C: results from astral-2 and -3 clinical trials","volume":"63","author":"Younossi","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eclinm.2019.12.007_bib0121","doi-asserted-by":"crossref","DOI":"10.1111\/liv.13462","article-title":"Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: the ASTRAL-5 study","author":"Younossi","year":"2017","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.eclinm.2019.12.007_bib0122","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jhep.2015.03.014","article-title":"Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir","volume":"63","author":"Younossi","year":"2015","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.eclinm.2019.12.007_bib0123","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/hep.27724","article-title":"Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials","volume":"61","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.eclinm.2019.12.007_bib0124","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/liv.12886","article-title":"The impact of ledipasvir\/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the sirius study","volume":"36","author":"Younossi","year":"2016","journal-title":"Liver Int"},{"issue":"22","key":"10.1016\/j.eclinm.2019.12.007_bib0125","article-title":"The impact of ledipasvir (LDV)\/sofosbuvir (SOF) combination on health-related quality of life (HRQL) and patient-reported outcomes (PROS) in cirrhotic patients with chronic hepatitis C (CH-C): the sirius study","volume":"62","author":"Younossi","year":"2015","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.eclinm.2019.12.007_bib0126","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12955-017-0598-8","article-title":"Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials","volume":"15","author":"Younossi","year":"2017","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"10.1016\/j.eclinm.2019.12.007_bib0127","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jhep.2017.01.025","article-title":"Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: a real-life observational study","volume":"66","author":"Zeng","year":"2017","journal-title":"J Hepatol"},{"issue":"1 Suppl 1","key":"10.1016\/j.eclinm.2019.12.007_bib0128","first-page":"59A","article-title":"A randomized, controlled, phase 3 trial of sofosbuvir\/ velpatasvir\/voxilaprevir or sofosbuvir\/velpatasvir for 12 weeks in direct acting antiviral-experienced patients with genotype 1-6 HCV infection: the POLARIS-4 study","volume":"63","author":"Zeuzem","year":"2016","journal-title":"Hepatology"},{"issue":"1 Supplement 1","key":"10.1016\/j.eclinm.2019.12.007_bib0129","first-page":"S109","article-title":"Ledipasvir\/sofosbuvir in treatment-Naive patients with chronic hcv infection and HIV\/HCV co-infection and in SOFexperienced patients","volume":"11","author":"Zhdanov","year":"2017","journal-title":"Hepatol Int"},{"issue":"1","key":"10.1016\/j.eclinm.2019.12.007_bib0130","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jvh.12247","article-title":"Historical epidemiology of hepatitis C virus (HCV) in selected countries","volume":"21 Suppl","author":"Bruggmann","year":"2014","journal-title":"J Viral Hepat"},{"issue":"1","key":"10.1016\/j.eclinm.2019.12.007_bib0131","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","year":"2015","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.eclinm.2019.12.007_bib0132","doi-asserted-by":"crossref","first-page":"ofz070","DOI":"10.1093\/ofid\/ofz070","article-title":"Predictors of hepatitis c treatment failure after using direct-acting antivirals in people living with human immunodeficiency virus","volume":"6","author":"Cachay","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.eclinm.2019.12.007_bib0133","doi-asserted-by":"crossref","first-page":"114","DOI":"10.7326\/0003-4819-158-2-201301150-00576","article-title":"Comparative effectiveness of antiviral treatment for hepatitis c virus infection in adults: a systematic review","volume":"158","author":"Chou","year":"2013","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.eclinm.2019.12.007_bib0134","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jval.2014.01.004","article-title":"Indirect treatment comparison\/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC good practice task force report","volume":"17","author":"Jansen","year":"2014","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.eclinm.2019.12.007_bib0135","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/cncr.31291","article-title":"Prevention of liver cancer with new curative hepatitis C antivirals: real-world challenges","volume":"124","author":"Soriano","year":"2018","journal-title":"Cancer"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537019302421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537019302421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:01:08Z","timestamp":1762887668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537019302421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":135,"alternative-id":["S2589537019302421"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2019.12.007","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2019.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100237"}}